CD8A and tuberculosis: In brief, patients with lower pre-treatment TB, higher density of activated CD8+ T cells and measurable Tregs within the TME may have a more favorable clinical evolution in terms of efficacy and toxicity after axi-cel, and these parameters could be included in the design of future clinical trials.